TY  - JOUR
AU  - Dragićević, Nina
AU  - Predić-Atkinson, Jelena
AU  - Nikolić, Bojan
AU  - Pajović, Snežana B.
AU  - Ivković, Sanja
AU  - Adžić, Miroslav
PY  - 2024
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12828
AB  - Introduction  Photodynamic therapy (PDT) has gained significant attention due to its superiority over conventional treatments. In the context of skin cancers and nonmalignant skin diseases, topical application of photosensitizer formulations onto affected skin, followed by illumination, offers distinct advantages. Topical PDT simplifies therapy by providing easy access to the skin, increasing drug concentration within the target area, and confining residual photosensitivity to the treated skin. However, the effectiveness of topical PDT is often hindered by challenges such as limited skin penetration or photosensitizer instability. Additionally, the hypoxic tumor environment poses further limitations. Nanocarriers present a promising solution to address these challenges. Areas covered  The objective of this review is to comprehensively explore and highlight the role of various nanocarriers in advancing topical PDT for the treatment of skin diseases. The primary focus is to address the challenges associated with conventional topical PDT approaches and demonstrate how nanotechnology-based strategies can overcome these challenges, thereby improving the overall efficiency and efficacy of PDT. Expert opinion  Nanotechnology has revolutionized the field of PDT, offering innovative tools to combat the unfavorable features of photosensitizers and hurdles in PDT. Nanocarriers enhance skin penetration and stability of photosensitizers, provide controlled drug release, reduce needed dose, increase production of reactive oxygen species, while reducing side effects, thereby improving PDT effectiveness.
T2  - Expert Opinion on Drug Delivery
T1  - Nanocarriers in topical photodynamic therapy
VL  - 21
IS  - 2
DO  - 10.1080/17425247.2024.2318460
ER  - 

@article{
author = "Dragićević, Nina and Predić-Atkinson, Jelena and Nikolić, Bojan and Pajović, Snežana B. and Ivković, Sanja and Adžić, Miroslav",
year = "2024",
abstract = "Introduction  Photodynamic therapy (PDT) has gained significant attention due to its superiority over conventional treatments. In the context of skin cancers and nonmalignant skin diseases, topical application of photosensitizer formulations onto affected skin, followed by illumination, offers distinct advantages. Topical PDT simplifies therapy by providing easy access to the skin, increasing drug concentration within the target area, and confining residual photosensitivity to the treated skin. However, the effectiveness of topical PDT is often hindered by challenges such as limited skin penetration or photosensitizer instability. Additionally, the hypoxic tumor environment poses further limitations. Nanocarriers present a promising solution to address these challenges. Areas covered  The objective of this review is to comprehensively explore and highlight the role of various nanocarriers in advancing topical PDT for the treatment of skin diseases. The primary focus is to address the challenges associated with conventional topical PDT approaches and demonstrate how nanotechnology-based strategies can overcome these challenges, thereby improving the overall efficiency and efficacy of PDT. Expert opinion  Nanotechnology has revolutionized the field of PDT, offering innovative tools to combat the unfavorable features of photosensitizers and hurdles in PDT. Nanocarriers enhance skin penetration and stability of photosensitizers, provide controlled drug release, reduce needed dose, increase production of reactive oxygen species, while reducing side effects, thereby improving PDT effectiveness.",
journal = "Expert Opinion on Drug Delivery",
title = "Nanocarriers in topical photodynamic therapy",
volume = "21",
number = "2",
doi = "10.1080/17425247.2024.2318460"
}

Dragićević, N., Predić-Atkinson, J., Nikolić, B., Pajović, S. B., Ivković, S.,& Adžić, M.. (2024). Nanocarriers in topical photodynamic therapy. in Expert Opinion on Drug Delivery, 21(2).
https://doi.org/10.1080/17425247.2024.2318460

Dragićević N, Predić-Atkinson J, Nikolić B, Pajović SB, Ivković S, Adžić M. Nanocarriers in topical photodynamic therapy. in Expert Opinion on Drug Delivery. 2024;21(2).
doi:10.1080/17425247.2024.2318460 .

Dragićević, Nina, Predić-Atkinson, Jelena, Nikolić, Bojan, Pajović, Snežana B., Ivković, Sanja, Adžić, Miroslav, "Nanocarriers in topical photodynamic therapy" in Expert Opinion on Drug Delivery, 21, no. 2 (2024),
https://doi.org/10.1080/17425247.2024.2318460 . .

TY  - JOUR
AU  - Adžić, Miroslav
AU  - Lukić, Iva
AU  - Mitić, Miloš
AU  - Glavonić, Emilija
AU  - Dragićević, Nina
AU  - Ivković, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11044
AB  - Major depressive disorder (MDD) afflicts approximately 5 % of the world population, and about 30–50 % of patients who receive classical antidepressant medications do not achieve complete remission (treatment resistant depressive patients). Emerging evidence suggests that targeting opioid receptors mu (MOP), kappa (KOP), delta (DOP), and the nociceptin/orphanin FQ receptor (NOP) may yield effective therapeutics for stress-related psychiatric disorders. As depression and pain exhibit significant overlap in their clinical manifestations and molecular mechanisms involved, it is not a surprise that opioids, historically used to alleviate pain, emerged as promising and effective therapeutic options in the treatment of depression. The opioid signaling is dysregulated in depression and numerous preclinical studies and clinical trials strongly suggest that opioid modulation can serve as either an adjuvant or even an alternative to classical monoaminergic antidepressants. Importantly, some classical antidepressants require the opioid receptor modulation to exert their antidepressant effects. Finally, ketamine, a well-known anesthetic whose extremely efficient antidepressant effects were recently discovered, was shown to mediate its antidepressant effects via the endogenous opioid system. Thus, although opioid system modulation is a promising therapeutical venue in the treatment of depression further research is warranted to fully understand the benefits and weaknesses of such approach.
T2  - Life Sciences
T2  - Life SciencesLife Sciences
T1  - Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine
VL  - 326
SP  - 121803
DO  - 10.1016/j.lfs.2023.121803
ER  - 

@article{
author = "Adžić, Miroslav and Lukić, Iva and Mitić, Miloš and Glavonić, Emilija and Dragićević, Nina and Ivković, Sanja",
year = "2023",
abstract = "Major depressive disorder (MDD) afflicts approximately 5 % of the world population, and about 30–50 % of patients who receive classical antidepressant medications do not achieve complete remission (treatment resistant depressive patients). Emerging evidence suggests that targeting opioid receptors mu (MOP), kappa (KOP), delta (DOP), and the nociceptin/orphanin FQ receptor (NOP) may yield effective therapeutics for stress-related psychiatric disorders. As depression and pain exhibit significant overlap in their clinical manifestations and molecular mechanisms involved, it is not a surprise that opioids, historically used to alleviate pain, emerged as promising and effective therapeutic options in the treatment of depression. The opioid signaling is dysregulated in depression and numerous preclinical studies and clinical trials strongly suggest that opioid modulation can serve as either an adjuvant or even an alternative to classical monoaminergic antidepressants. Importantly, some classical antidepressants require the opioid receptor modulation to exert their antidepressant effects. Finally, ketamine, a well-known anesthetic whose extremely efficient antidepressant effects were recently discovered, was shown to mediate its antidepressant effects via the endogenous opioid system. Thus, although opioid system modulation is a promising therapeutical venue in the treatment of depression further research is warranted to fully understand the benefits and weaknesses of such approach.",
journal = "Life Sciences, Life SciencesLife Sciences",
title = "Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine",
volume = "326",
pages = "121803",
doi = "10.1016/j.lfs.2023.121803"
}

Adžić, M., Lukić, I., Mitić, M., Glavonić, E., Dragićević, N.,& Ivković, S.. (2023). Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. in Life Sciences, 326, 121803.
https://doi.org/10.1016/j.lfs.2023.121803

Adžić M, Lukić I, Mitić M, Glavonić E, Dragićević N, Ivković S. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. in Life Sciences. 2023;326:121803.
doi:10.1016/j.lfs.2023.121803 .

Adžić, Miroslav, Lukić, Iva, Mitić, Miloš, Glavonić, Emilija, Dragićević, Nina, Ivković, Sanja, "Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine" in Life Sciences, 326 (2023):121803,
https://doi.org/10.1016/j.lfs.2023.121803 . .